Communication from Polymer Factory Sweden AB’s Extra General Meeting on 15 February 2023

Today, 15 February 2023, the Extra General Meeting of Polymer Factory Sweden AB (publ) was held (the "EGM"). Below is a summary of the decision that was made. The decision was made with the required majority.

Resolution by the Board of Directors on a rights issue of shares

The EGM resolved to approve the Board of Directors decision to increase the company's share capital by a maximum of SEK 548,831.60 through a new issue of not more than 5,488,316 shares.

For the issue, the following conditions shall apply:

1. The issue shall be made with preferential rights for the shareholders of the company. For each existing share, one (1) subscription right is obtained. Five (5) such subscription rights entitle you to subscribe for four (4) new shares.

2. The record date in the share register maintained by Euroclear Sweden AB for determining which shareholders are entitled to participate in the issue with preferential rights shall be 22 February 2023. Others can also subscribe in the issue.

3. For each subscribed share, SEK 1.60 shall be paid in cash. Amounts in excess of the quotient value shall be added to the free premium fund.

4. Subscription of shares shall take place during the period from and including 24 February 2023 to and including 10 March 2023. Subscription with the support of preferential rights shall be made by simultaneous cash payment. Subscription made without the support of subscription rights must be made on a special subscription list and payment must be made no later than the fourth banking day after the notification of allotment has been sent to the subscriber. The Board of Directors shall have the right to extend the time for subscription and payment.

5. In the event that not all shares are subscribed for with preferential rights in accordance with the above, the Board of Directors shall, within the framework of the issue's maximum amount, decide on the allotment of shares to another person who has subscribed for shares without the support of preferential rights and decide how distribution between subscribers shall thereby take place.

In the first instance, allotment of new shares subscribed for without the support of subscription rights shall be made to such subscribers who have also subscribed for new shares with the support of subscription rights, regardless of whether the subscriber was a shareholder on the record date or not, and in the event that allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of subscription rights if exercised for subscription of new shares and, to the extent that this cannot be done, by drawing lots.

In the alternative, allotment of new shares subscribed for without the exercise of subscription rights shall be made to others who have subscribed without the support of subscription rights, and in the event that allotment to these cannot be made in full, allotment shall be made pro rata in proportion to the number of new shares that each subscribed for and, to the extent that this cannot be done, by lot.

Thirdly, allotment of new shares subscribed for without the support of subscription rights shall be made to the underwriters in proportion to the amount of the guarantee commitments made, and to the extent that this cannot be done, by drawing lots.

6. The new shares shall entitle to dividends for the first time on the record date for dividends that occurs immediately after the new shares have been registered with the Swedish Companies Registration Office.

7. The Board of Directors or the person appointed by the Board of Directors is authorized to decide on minor corrections required for registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.